Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research

被引:16
作者
Huskins, W. Charles [1 ]
Fowler, Vance G., Jr. [2 ]
Evans, Scott [3 ]
机构
[1] Mayo Clin, Coll Med, Rochester, MN USA
[2] Duke Univ, Durham, NC USA
[3] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
关键词
research design; clinical trials; randomized controlled trials; infection control; drug resistance; microbial; DATA MONITORING COMMITTEES; SAMPLE-SIZE; RANDOMIZATION; OPPORTUNITIES; ISSUES;
D O I
10.1093/cid/cix907
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Clinical trials with adaptive designs use data that accumulate during the course of the study to modify study elements in a prespecified manner. The goal is to provide flexibility such that a trial can serve as a definitive test of its primary hypothesis, preferably in a shorter time period, involving fewer human subjects, and at lower cost. Elements that may be modified include the sample size, end points, eligible population, randomization ratio, and interventions. Accumulating data used to drive these modifications include the outcomes, subject enrollment (including factors associated with the outcomes), and information about the application of the interventions. This review discusses the types of adaptive designs for clinical trials, emphasizing their advantages and limitations in comparison with conventional designs, and opportunities for applying these designs to healthcare epidemiology research, including studies of interventions to prevent healthcare-associated infections, combat antimicrobial resistance, and improve antimicrobial stewardship.
引用
收藏
页码:1140 / 1146
页数:7
相关论文
共 52 条
[1]   The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group [J].
Anderson, Deverick J. ;
Jenkins, Timothy C. ;
Evans, Scott R. ;
Harris, Anthony D. ;
Weinstein, Robert A. ;
Tamma, Pranita D. ;
Han, Jennifer H. ;
Banerjee, Ritu ;
Patel, Robin ;
Zaoutis, Theoklis ;
Lautenbach, Ebbing .
CLINICAL INFECTIOUS DISEASES, 2017, 64 :S36-S40
[2]   Sample Size Considerations in Clinical Trials When Comparing Two Interventions Using Multiple Co-Primary Binary Relative Risk Contrasts [J].
Ando, Yuki ;
Hamasaki, Toshimitsu ;
Evans, Scott R. ;
Asakura, Koko ;
Sugimoto, Tomoyuki ;
Sozu, Takashi ;
Ohno, Yuko .
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2015, 7 (02) :81-94
[3]  
[Anonymous], 2017, PLATFORM TRIAL EVALU
[4]  
[Anonymous], 2017, REMAP CAP RANDOMIZED
[5]   Views on Emerging Issues Pertaining to Data Monitoring Committees for Adaptive Trials [J].
Antonijevic, Zoran ;
Gallo, Paul ;
Chuang-Stein, Christy ;
Dragalin, Vladimir ;
Loewy, John ;
Menon, Sandeep ;
Miller, Eva R. ;
Morgan, Caroline Claire ;
Sanchez, Matilde .
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2013, 47 (04) :495-502
[6]  
Asakura K., 2015, APPL STAT BIOMEDICIN, P235, DOI DOI 10.1007/978-3-319-12694-4_14
[7]   Sample size determination in group-sequential clinical trials with two co-primary endpoints [J].
Asakura, Koko ;
Hamasaki, Toshimitsu ;
Sugimoto, Tomoyuki ;
Hayashi, Kenichi ;
Evans, Scott R. ;
Sozu, Takashi .
STATISTICS IN MEDICINE, 2014, 33 (17) :2897-2913
[8]   Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls [J].
Bauer, Peter ;
Bretz, Frank ;
Dragalin, Vladimir ;
Koenig, Franz ;
Wassmer, Gernot .
STATISTICS IN MEDICINE, 2016, 35 (03) :325-347
[9]   Adaptive Randomization of Neratinib in Early Breast Cancer [J].
Buyse, Marc ;
Saad, Everardo D. ;
Burzykowski, Tomasz .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (16) :1591-1592
[10]   The Platform Trial An Efficient Strategy for Evaluating Multiple Treatments [J].
Berry, Scott M. ;
Connor, Jason T. ;
Lewis, Roger J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (16) :1619-1620